Abstract

Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features. This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric disease despite extensive genetic heterogeneity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

References

  1. 1.

    et al. A copy number variation morbidity map of developmental delay. Nat. Genet. 43, 838–846 (2011).

  2. 2.

    et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet. Med. 13, 777–784 (2011).

  3. 3.

    et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol. Psychiatry 18, 1090–1095 (2013).

  4. 4.

    et al. Clinical significance of de novo and inherited copy-number variation. Hum. Mutat. 34, 1679–1687 (2013).

  5. 5.

    et al. De novo mutations in epileptic encephalopathies. Nature 501, 217–221 (2013).

  6. 6.

    et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921–1929 (2012).

  7. 7.

    et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154, 518–529 (2013).

  8. 8.

    et al. De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285–299 (2012).

  9. 9.

    et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 93, 249–263 (2013).

  10. 10.

    et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485, 242–245 (2012).

  11. 11.

    et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246–250 (2012).

  12. 12.

    et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380, 1674–1682 (2012).

  13. 13.

    et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237–241 (2012).

  14. 14.

    et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 498, 220–223 (2013).

  15. 15.

    et al. A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders. Am. J. Hum. Genet. 94, 415–425 (2014).

  16. 16.

    et al. Segmental duplications mediate novel, clinically relevant chromosome rearrangements. Hum. Mol. Genet. 18, 2957–2962 (2009).

  17. 17.

    et al. Distinctive phenotype in 9 patients with deletion of chromosome 1q24-q25. Am. J. Med. Genet. A. 155A, 1336–1351 (2011).

  18. 18.

    et al. Investigation of NRXN1 deletions: clinical and molecular characterization. Am. J. Med. Genet. A. 161A, 717–731 (2013).

  19. 19.

    et al. A rare 3q13.31 microdeletion including GAP43 and LSAMP genes. Mol. Cytogenet. 6, 52 (2013).

  20. 20.

    , , , & 12p13 rearrangements: 6 Mb deletion responsible for ID/MCA and reciprocal duplication without clinical responsibility. Am. J. Med. Genet. A. 158A, 1071–1076 (2012).

  21. 21.

    et al. MEF2C haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways. Neurogenetics 14, 99–111 (2013).

  22. 22.

    et al. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. PLoS ONE 4, e6568 (2009).

  23. 23.

    et al. Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats. Hum. Mutat. 33, 165–179 (2012).

  24. 24.

    et al. The phenotype of recurrent 10q22q23 deletions and duplications. Eur. J. Hum. Genet. 19, 400–408 (2011).

  25. 25.

    et al. Further delineation of the SATB2 phenotype. Eur. J. Hum. Genet. 22, 1034–1039 (2014).

  26. 26.

    et al. Chromosomal imbalances in patients with congenital cardiac defects: a meta-analysis reveals novel potential critical regions involved in heart development. Congenit. Heart Dis. 10.1111/chd.12179 (11 April 2014).

  27. 27.

    et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. J. Med. Genet. 47, 22–29 (2010).

  28. 28.

    et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 153B, 937–947 (2010).

  29. 29.

    et al. Recurrent HERV-H–mediated 3q13.2-q13.31 deletions cause a syndrome of hypotonia and motor, language, and cognitive delays. Hum. Mutat. 34, 1415–1423 (2013).

  30. 30.

    et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat. Genet. 42, 1021–1026 (2010).

  31. 31.

    , , , & PTEN mutation in a family with Cowden syndrome and autism. Am. J. Med. Genet. 105, 521–524 (2001).

  32. 32.

    et al. Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome. Nat. Genet. 44, 639–641 (2012).

  33. 33.

    A catalog of SCN1A variants. Brain Dev. 31, 114–130 (2009).

  34. 34.

    et al. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. Nat. Genet. 44, 379–380 (2012).

  35. 35.

    et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am. J. Hum. Genet. 89, 551–563 (2011).

  36. 36.

    et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338, 1619–1622 (2012).

  37. 37.

    & The Simons Simplex Collection: a resource for identification of autism genetic risk factors. Neuron 68, 192–195 (2010).

  38. 38.

    et al. Segmental duplications and copy-number variation in the human genome. Am. J. Hum. Genet. 77, 78–88 (2005).

  39. 39.

    et al. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. Clin. Genet. 79, 296–299 (2011).

  40. 40.

    et al. Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder. Am. J. Hum. Genet. 92, 221–237 (2013).

  41. 41.

    et al. Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome. J. Med. Genet. 48, 117–122 (2011).

  42. 42.

    et al. 372 kb microdeletion in 18q12.3 causing SETBP1 haploinsufficiency associated with mild mental retardation and expressive speech impairment. Eur. J. Med. Genet. 55, 216–221 (2012).

  43. 43.

    et al. Subtelomeric deletion of chromosome 10p15.3: clinical findings and molecular cytogenetic characterization. Am. J. Med. Genet. A. 158A, 2152–2161 (2012).

  44. 44.

    & The conserved Mynd domain of BS69 binds cellular and oncoviral proteins through a common PXLXP motif. J. Biol. Chem. 277, 4906–4910 (2002).

  45. 45.

    et al. Structural and functional analysis of the DEAF-1 and BS69 MYND domains. PLoS ONE 8, e54715 (2013).

  46. 46.

    & The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. Oncogene 19, 1538–1546 (2000).

  47. 47.

    et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 505, 361–366 (2014).

  48. 48.

    et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat. Genet. 42, 483–485 (2010).

  49. 49.

    & A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. Am. J. Med. Genet. 1, 361–375 (1978).

  50. 50.

    et al. Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942–946 (2013).

  51. 51.

    et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat. Genet. 45, 18–24 (2013).

  52. 52.

    et al. ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. Nature 508, 263–268 (2014).

  53. 53.

    et al. BS69 undergoes SUMO modification and plays an inhibitory role in muscle and neuronal differentiation. Exp. Cell Res. 315, 3543–3553 (2009).

  54. 54.

    et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179–184 (2014).

  55. 55.

    et al. Clinical and molecular characterization of individuals with recurrent genomic disorder at 10q22.3q23.2. Clin. Genet. 78, 162–168 (2010).

  56. 56.

    et al. De novo copy number variants associated with intellectual disability have a paternal origin and age bias. J. Med. Genet. 48, 776–778 (2011).

  57. 57.

    et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur. J. Hum. Genet. 18, 1196–1201 (2010).

  58. 58.

    & Outlier detection for skewed data. J. Chemometr. 22, 235–246 (2008).

  59. 59.

    , , , & Estimates of penetrance for recurrent pathogenic copy-number variations. Genet. Med. 15, 478–481 (2013).

  60. 60.

    & Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Stat. Soc. 57, 289–300 (1995).

Download references

Acknowledgements

We thank F. Hormozdiari, M. Dennis and T. Brown for useful discussions and for editing the manuscript. B.P.C. is supported by a fellowship from the Canadian Institutes of Health Research. This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk/. J.A.R. and B.S.T. are employees of Signature Genomics Laboratories, LLC, a subsidiary of PerkinElmer, Inc. This work was supported by US National Institute of Mental Health grant MH101221 and Paul G. Allen Family Foundation Award 11631 to E.E.E. E.E.E. is an Allen Distinguished Investigator and an investigator of the Howard Hughes Medical Institute.

Author information

Author notes

    • Brian J O'Roak
    •  & Marco Fichera

    Present addresses: Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Portland, Oregon, USA (B.J.O.) and Medical Genetics, University of Catania, Catania, Italy (M.F.).

Affiliations

  1. Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington, USA.

    • Bradley P Coe
    • , Kali Witherspoon
    • , Carl Baker
    • , Nik Krumm
    • , Brian J O'Roak
    • , Jay Shendure
    •  & Evan E Eichler
  2. Signature Genomics Laboratories, LLC, PerkinElmer, Inc., Spokane, Washington, USA.

    • Jill A Rosenfeld
    •  & Beth S Torchia
  3. Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

    • Bregje W M van Bon
    • , Anneke T Vulto-van Silfhout
    • , Lisenka E L M Vissers
    • , Janneke H Schuurs-Hoeijmakers
    • , Alex Hoischen
    • , Rolph Pfundt
    • , Nicole de Leeuw
    • , Margot R F Reijnders
    • , Jayne Y Hehir-Kwa
    •  & Bert B A de Vries
  4. SA Pathology, North Adelaide, South Australia, Australia.

    • Bregje W M van Bon
    • , Kathryn L Friend
    • , Marie Shaw
    • , Elizabeth Thompson
    • , Eric Haan
    •  & Jozef Gécz
  5. IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Associazione Oasi Maria Santissima, Troina, Italy.

    • Paolo Bosco
    • , Serafino Buono
    • , Antonino Alberti
    • , Rosa Pettinato
    • , Marco Fichera
    •  & Corrado Romano
  6. Department of Pediatrics, University of Washington, Seattle, Washington, USA.

    • Gemma L Carvill
    •  & Heather C Mefford
  7. Representing the Autism Phenome Project, MIND Institute, University of California, Davis, Sacramento, California, USA.

    • Deana Li
    •  & David Amaral
  8. Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia.

    • Natasha Brown
    •  & Paul J Lockhart
  9. Barwon Child Health Unit, Barwon Health, Geelong, Victoria, Australia.

    • Natasha Brown
  10. Murdoch Childrens Research Institute, University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia.

    • Paul J Lockhart
  11. Florey Institute, University of Melbourne, Austin Health and Royal Children's Hospital, Melbourne, Victoria, Australia.

    • Ingrid E Scheffer
  12. Division of Developmental and Behavioral Pediatrics, Mayo Clinic, Rochester, Minnesota, USA.

    • Raymond Tervo
  13. Center for Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

    • Hilde Peeters
  14. Leuven Autism Research (LAuRes), Leuven, Belgium.

    • Hilde Peeters
  15. School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, Australia.

    • Elizabeth Thompson
    •  & Eric Haan
  16. Robinson Institute, University of Adelaide, Adelaide, South Australia, Australia.

    • Jozef Gécz
  17. Howard Hughes Medical Institute, Seattle, Washington, USA.

    • Evan E Eichler

Authors

  1. Search for Bradley P Coe in:

  2. Search for Kali Witherspoon in:

  3. Search for Jill A Rosenfeld in:

  4. Search for Bregje W M van Bon in:

  5. Search for Anneke T Vulto-van Silfhout in:

  6. Search for Paolo Bosco in:

  7. Search for Kathryn L Friend in:

  8. Search for Carl Baker in:

  9. Search for Serafino Buono in:

  10. Search for Lisenka E L M Vissers in:

  11. Search for Janneke H Schuurs-Hoeijmakers in:

  12. Search for Alex Hoischen in:

  13. Search for Rolph Pfundt in:

  14. Search for Nik Krumm in:

  15. Search for Gemma L Carvill in:

  16. Search for Deana Li in:

  17. Search for David Amaral in:

  18. Search for Natasha Brown in:

  19. Search for Paul J Lockhart in:

  20. Search for Ingrid E Scheffer in:

  21. Search for Antonino Alberti in:

  22. Search for Marie Shaw in:

  23. Search for Rosa Pettinato in:

  24. Search for Raymond Tervo in:

  25. Search for Nicole de Leeuw in:

  26. Search for Margot R F Reijnders in:

  27. Search for Beth S Torchia in:

  28. Search for Hilde Peeters in:

  29. Search for Elizabeth Thompson in:

  30. Search for Brian J O'Roak in:

  31. Search for Marco Fichera in:

  32. Search for Jayne Y Hehir-Kwa in:

  33. Search for Jay Shendure in:

  34. Search for Heather C Mefford in:

  35. Search for Eric Haan in:

  36. Search for Jozef Gécz in:

  37. Search for Bert B A de Vries in:

  38. Search for Corrado Romano in:

  39. Search for Evan E Eichler in:

Contributions

B.P.C. and E.E.E. designed the study. B.P.C. performed the data analysis. B.P.C., K.W. and C.B. performed array CGH, MIP sequencing and Sanger validation. J.A.R. and B.S.T. supervised array CGH experiments and coordinated clinical data collection at Signature Genomics. B.W.M.v.B., A.T.V.-v.S., P.B., K.L.F., S.B., L.E.L.M.V., J.H.S.-H., A.H., D.L., D.A., N.B., P.J.L., I.E.S., A.A., R. Pettinato, R.T., N.d.L., M.R.F.R., H.P., E.T., M.F., M.S., H.C.M., E.H., C.R., J.G. and B.B.A.d.V. provided clinical samples for resequencing, clinical reports and inheritance testing. J.Y.H.-K., R. Pfundt and N.d.L. curated the Nijmegen de novo CNV calls. B.P.C., K.W., C.B., B.J.O., J.S., and E.E.E. designed the MIP gene panel. G.L.C. and H.C.M. identified two SETBP1 variants in an independent screen. N.K. curated published de novo mutations. B.P.C. and E.E.E. wrote the manuscript. All authors have read and approved the final version of the manuscript.

Competing interests

J.A.R. and B.S.T. are employees of Signature Genomics Laboratories, LLC, a subsidiary of PerkinElmer, Inc. E.E.E. is on the scientific advisory board (SAB) of DNAnexus, Inc., and was an SAB member of Pacific Biosciences, Inc. (2009–2013) and SynapDx Corp. (2011–2013).

Corresponding author

Correspondence to Evan E Eichler.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–7, Supplementary Tables 1–3, 5, 8, 9 and 11, and Supplementary Note.

Excel files

  1. 1.

    Supplementary Tables 4, 6, 7 and 10

    Supplementary Tables 4, 6, 7 and 10.

  2. 2.

    Supplementary Data Set 1

    CNV window counts and P values.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.3092

Further reading